|Reference : Platelet-rich plasma (PRP) to treat upper patellar tendinopathies|
|Scientific congresses and symposiums : Paper published in a book|
|Human health sciences : Orthopedics, rehabilitation & sports medicine|
|Platelet-rich plasma (PRP) to treat upper patellar tendinopathies|
|Kaux, Jean-François [Université de Liège - ULg > Département des sciences de la motricité > Département des sciences de la motricité >]|
|Croisier, Jean-Louis [Université de Liège - ULg > Département des sciences de la motricité > Kinésithérapie générale et réadaptation >]|
|SIMONI, Paolo [Centre Hospitalier Universitaire de Liège - CHU > > Imagerie de l'appareil locomoteur >]|
|Brabant, Gautier [> >]|
|Lapraille, Stuart [> >]|
|Lonneux, Vincent [> >]|
|Noël, David [> >]|
|Rodriguez de la Cruz, Carlos [Université de Liège - ULg > Département des sciences de la motricité > Physiologie humaine et physiologie de l'effort physique >]|
|Collette, Julien [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques >]|
|LE GOFF, Caroline [Centre Hospitalier Universitaire de Liège - CHU > > Chimie médicale >]|
|Gothot, André [Université de Liège - ULg > Département des sciences cliniques > Département des sciences cliniques >]|
|Crielaard, Jean-Michel [Université de Liège - ULg > Département des sciences de la motricité > Evaluation et entraînement des aptitudes physiques >]|
|Book of Abstracts of the 17th annual Congress of the ECSS|
|De Geus, B|
|17th Annual Congress of the ECSS|
|4-7 july 2012|
|[en] Introduction: Tendinopathies, especially upper patellar tendinopathy also known as jumper’s knee, often remain rebel to conservative treatments. Several experimental studies have shown the healing properties of platelet and their growth factors. These factors have the potentiality to improve healing of different tissues: bones, muscles, tendons... Researches have specifically demonstrated the platelets action as mediator and/or enhancer of tissue healing. On the other hand, such treatment has been totally removed of list of doping treatments. The aim of our study was to investigate the effect of 1 injection of PRP in patients suffering from chronic jumper’s knee.
Methods: Patients performed imaging (US and MRI) and functional assessments, and a clinical examination using an algometer, before treatment and 6 weeks after PRP treatment. They were also invited to answer to questionnaire relative to pain and functional status. PRP was obtained from autologous blood using an apheresis system (COM.TEC, Fresenius). The injection of 6mL of PRP was realised without local anaesthesia into the proximal insertion of the patellar tendon. A 48h rest-time was recommended after infiltration. Afterwards, a submaximal eccentric reeducation was initiated 1 week after infiltration 3 times a week during 5 weeks. In case of pain, anti-inflammatory drugs were prohibited and patient were encouraged to take class I or II painbrakers. Our protocol was approved by Ethic Committee of University and University Hospital of Liège.
Results: Eighteen patients with jumper’s knee were included in our study. Pre-injection tests revealed pain of the upper part of the patellar tendon just below the patella, associated with loss of function. Imaging exams confirmed diagnosis. Six weeks post-injection, the clinical status was improved for the majority of the patients, with a significant decrease of algo-functional scores. The pain reported during functional assessments was decreased (in particular for the eccentric actions), yet no significant improvement of physical performances was observed. We found no significant differences between imaging exams before and 6 weeks after PRP injection.
Conclusion: One in situ injection of PRP clinically improved patients with jumper’s knee 6 weeks after treatment. Most patients reported a decrease of pain during day-life and through physical activities. However nor functional performances neither imaging were improved. A followup at 3 months is actually in process to evaluate more long term efficacy of PRP treatment.
|File(s) associated to this reference|
All documents in ORBi are protected by a user license.